Fermenta Biotech Q2 FY26: Capex ₹12 Cr
Q2 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹130Cr
- +37% YoY
- −4.4% QoQ
- Net profit
- ₹18Cr
- +62.1% YoY
- −16.5% QoQ
- Margin
- 20.46%
- +0.7 pp YoY
- −0.3 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Fermenta Biotech Ltd Q2 FY26 key numbers
- Revenue
- Q2FY26 Revenue: INR 135.7 crore, up 39% YoY.
As stated in Fermenta Biotech Ltd's Q2 FY26 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Fermenta Biotech Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2FY26 Revenue: INR 135.7 crore, up 39% YoY - H1FY26 Revenue: INR 280.7 crore, up 57% YoY - Human nutrition segment volumes grew 74% over H1FY25 - Animal nutrition segment volumes grew 6% over H Q2FY26 Financials: - EBITDA: ₹32.1 crore (up 48% YoY) - Profit after tax (PAT): ₹18.0 crore (up 62% YoY) - Revenue: ₹135.7 crore (up 39% YoY) - H1FY26 Financial Highlights: - EBITDA: ₹69.1 crore (up 173% YoY) - PAT: ₹39.6 crore (up 664% YoY) - Revenue: ₹280.7 crore (up 57% YoY) - EBITDA Margin: sustained at 25.9% for H1FY26 - Net Profit Margin: 14.9% in H1FY26 (from Performance Ratios on page 10) - Margin Outlook:
From Fermenta Biotech Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2FY26 Revenue: INR 135.7 crore, up 39% YoY
- H1FY26 Revenue: INR 280.7 crore, up 57% YoY
- Human nutrition segment volumes grew 74% over H1FY25
- Animal nutrition segment volumes grew 6% over H1FY25; average realization rose 35%
2 more points from Fermenta Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- H1FY26 investing cash flow shows ₹12 crore spent on Capex for growth initiatives (Page 8).
- Only reference to "strategic capital investment" deployed for growth initiatives (Page 8).
- In September 2025, the board approved the transfer of the Environment Division as a going concern to a wholly owned subsidiary for INR 19 crore; effective 1 October 2025 (Page 5).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Fermenta Biotech Ltd said on order book & pipeline — free account, 30 seconds.
Fermenta Biotech Ltd — Quarterly revenue & net profit
Fermenta Biotech Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 130 | 95 | +37% | 136 | -4.4% |
| Operating profit (EBITDA) | 27 | 19 | +41.9% | 28 | -5.7% |
| Operating margin | 20.46% | 19.76% | +0.7 pp | 20.73% | -0.3 pp |
| Profit before tax | 24 | 12 | +103.7% | 28 | -14.3% |
| Net profit (PAT) | 18 | 11 | +62.1% | 22 | -16.5% |
| EPS (₹) | 6.14 | 3.87 | +58.7% | 7.42 | -17.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹133 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fermenta Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Fermenta Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fermenta Biotech Ltd Q2 FY26 results?
Q2FY26 Revenue: INR 135.7 crore, up 39% YoY - H1FY26 Revenue: INR 280.7 crore, up 57% YoY - Human nutrition segment volumes grew 74% over H1FY25 - Animal nutrition segment volumes grew 6% over H Q2FY26 Financials: - EBITDA: ₹32.1 crore (up 48% YoY) - Profit after tax (PAT): ₹18.0 crore (up 62% YoY) - Revenue: ₹135.7 crore (up 39% YoY) - H1FY26 Financial Highlights: - EBITDA: ₹69.1 crore (up 173% YoY) - PAT: ₹39.6 crore (up 664% YoY) - Revenue: ₹280.7 crore (up 57% YoY) - EBITDA Margin: sustained at 25.9% for H1FY26 - Net Profit Margin: 14.9% in H1FY26 (from Performance Ratios on page 10) - Margin Outlook:
What is Fermenta Biotech Ltd share price analysis?
Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fermenta Biotech Ltd planning capital expenditure?
H1FY26 investing cash flow shows ₹12 crore spent on Capex for growth initiatives (Page 8).
Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
